Are you working with a poorly water-soluble API? Join Lubrizol Life Science (LLS Health) at Partnerships in Drug Delivery (PODD) on October 24 and 25 as we showcase our solubility-enhancing excipients and CDMO services for BCS Class II and IV APIs:
Featured Presentations
Solving Injectable Solubility Issues with Apisolex™ Polyamino Acid Polymers
Date: October 24th
Track: 1A - Injectable Formulation
Time: 3:15 PM
Key Points:
- Solubility issues plague more than two of every three APIs in the pipeline.
- While a variety of solutions exist including the use of various excipients, the problem persists.
- Discover Apisolex™, a non-toxic, non-immunogenic, biocompatible, biodegradable alternative to PEG that can increase the solubility of injectable-grade API by up to 50,000-fold.
Learn more about Apisolex here!
Solving Oral Solubility Issues with Apinovex™ Polyacrylic Acid Polymers
Date: October 24th
Track: 2A - Oral, Mucosal, Nasal and other Non-Injectable Technologies
Time: 3:00 PM
Key Points:
- Increasing solubility and improving bioavailability are the most common challenges facing pharmaceutical scientists today
- Integrating novel excipients into your formulation programs offers a straightforward method to solubilizing challenging BCS II and IV compounds, especially when traditional excipients fall short
- Discover Apinovex™, a technology for amorphous solid dispersions that enables stable drug loading of up to 80% for innovative NCE and 505(b)(2) formulations
Learn more about Apinovex here!
We look forward to seeing you at PODD 2022!
